2118349-31-6
Chemical Structure
Lodapolimab
Synonym(s): LY3300054
- CAS No.: 2118349-31-6
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Lodapolimab]
Biological Activity: Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lodapolimab | 99.71% | Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Li Y, et al. Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. Journal for immunotherapy of cancer. 2018 Apr 30;6(1):31. [Content Brief]
- [2]. WHO Drug Information, Vol. 34, No. 1, 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO
- [3]. Do KT, et al. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer immunology, immunotherapy : CII. 2021 Oct;70(10):2991-3000. [Content Brief]
Keywords
